Olema Pharma up on expanded partnership with Novartis

Olema Pharmaceuticals

10/10/2023 14:59

** Shares of clinical-stage biopharma company Olema
Pharmaceuticals  OLMA.O  up 1.8% at $13.2 
    ** Olema reports expansion of clinical collaboration and
supply agreement with Switzerland-based Novartis  NOVN.S  
    ** The amended pact to increase size of an ongoing
early-to-mid-stage trial 
    ** The trial is testing OLMA's lead drug candidate,
palazestrant in combination with Novartis' anti-cancer medicine
ribociclib to treat a type of breast cancer 
    ** Olema first signed a clinical collaboration and supply
agreement with NOVN in July 2020, the agreement was amended and
restated in January 2022
    ** YTD, stock up about 438% 


 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))